A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
Recruiting · NCT06512454
Conditions: Alpha1-Antitrypsin Deficiency
At a glance
- Research payments reported, 2025
- $37,333
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 500
About the trial
- Sponsor
- Takeda
- Tested
- No Intervention (other)
- Dates
- Started 2024-09-25; completion 2031-12-31
- Results posted
- Not yet
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells and also leads to low blood levels of AAT (called Alpha-1 Antitrypsin Deficiency or AATD). Over time, this build up leads to different stages of liver problems, if not treated. This is called natural history of AATD. The main aim of this study is to learn about liver problems caused by AATD in adults when not treated over 4 to 8 years. Other aims are to learn what can predict the AATD-liver condition starting and getting better or worse, describe how this condition is currently…
From ClinicalTrials.gov, last updated 2026-07-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $37,333 in research payments for this study in 2025 (35 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.